Previous reports in other cancer models have demonstrated the pro-tumor function of RBBP9 through either the inhibition of the cell cycle regulatory protein RB or the serine hydrolase activity-mediated suppression of the TGF-β pathway.15 The gene discussed is RB1; the disease is cancer.